Dianthus Therapeutics, Inc. /DE/
DNTH · XNASCIK 1690585fmd_04QN87BN6RC9DX10SBA5RYYAMDManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2016 to Sep 30, 2026, 40 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | – | 1 | 6 | 3 | 6 | 2 |
| Research and development | 6 | 28 | 41 | 59 | 51 | 13 | 29 | 33 | 83 | 146 |
| Total operating expenses | 9 | 36 | 60 | 83 | 79 | 15 | 36 | 51 | 108 | 180 |
| Operating income | (9) | (36) | (60) | (83) | (79) | (13) | (30) | (48) | (102) | (178) |
| Interest expense | 0 | – | – | – | – | – | – | – | – | – |
| Interest and investment income | – | 0 | 2 | 6 | 4 | 4 | 4 | 3 | 11 | 10 |
| Other non-operating income (expense) | (0) | 0 | 2 | – | – | (0) | 1 | 5 | 17 | 16 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | (9) | (35) | (58) | (77) | (75) | (13) | (28) | (44) | (85) | (162) |
| Net income to common shareholders | (10) | (36) | (58) | (77) | – | – | – | – | – | – |